In light of all this, the aim of this narrative review is, starting from the structural and functional principles of GLP-1, to examine the effectiveness of the pharmacological modulation of GLP-1 through specific agonists, both for the management of weight loss, specifically in patients with IBD, and to assess the available evidence on the impact of such treatment on disease activity and its safety in patients with IBD, including the influence of various relevant parameters such as bowel preparation before endoscopic procedures. This evidence concerns the gene GCG and inflammatory bowel disease.